Skip to main content
Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc. — Investor Relations & Filings

Ticker · AKRO ISIN · US00973Y1082 LEI · 549300SI3KG74LBE2955 US Professional, scientific and technical activities
Open in API
Filings indexed 719 across all filing types
Latest filing 2023-10-10 Regulatory Filings
Country US United States of America
Listing US AKRO

About Akero Therapeutics, Inc.

https://akerotx.com/

Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates that shareholders should know about. The text includes a press release about clinical trial results and a slide presentation, both furnished as exhibits. The document does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is not a transcript, audit report, or other specialized filing. The content is primarily an update on clinical study results and a presentation, which fits the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories. The document length (10,762 characters) and content confirm it is a full 8-K report, not just a brief announcement. Therefore, the best classification is Regulatory Filings (RNS).
2023-10-10 English
4
Director's Dealing
2023-10-05 English
4
Director's Dealing
2023-10-05 English
Regulatory Filings 2023
Regulatory Filings
2023-10-03 English
Regulatory Filings 2023
Regulatory Filings
2023-10-03 English
4
Director's Dealing
2023-09-26 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.